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The importance of the hepatic venous pressure gradient
(HVPG) in selecting patients with hepatocellular carcinoma
(HCC) for liver resection (LR) has been somewhat controver-
sial. Recently, Boleslawski et al. prospectively evaluated a
cohort of 40 patients undergoing LR for HCC; the authors
aimed to identify the impact ofHVPG values and clinical signs
of portal hypertension (esophageal varices or splenomegaly
with a platelet count ,100,000/mm3) on postoperative
outcomes (1). The study showed that liver dysfunction and
90-day postoperative mortality rates were associated with
high HVPG values (p=0.017 and 0.026, respectively). In
contrast, the presence of clinical features of portal hyperten-
sion was not associated with either liver dysfunction or short-
term mortality. The authors concluded that the HVPG should
be measured routinely in HCC patients prior to LR. Clinical
practice guidelines from the European Association for the
Study of the Liver (EASL) and the American Association for
the Study of Liver Diseases (AASLD) suggest that clinical
parameters can be used as an alternative to HPVG in
determining the presence of clinically relevant portal hyper-
tension (2,3). Consequently, HVPG assessment may not be
necessary in all LR candidates (4). Although the Boleslawski et
al. study examined an important aspect of LR for HCC
patients, some concerns should be addressed.
There is no clear maximum tumor size that contra-
indicates LR in HCC patients with a single nodule (2,3).
Nevertheless, in a patient with well-preserved liver function
and a single tumor up to 5 cm, the presence of portal
hypertension is accepted as an adverse prognostic factor
that is associated with reduced and long-term patient
survival (5,6). In 1996, Bruix et al. first reported the negative
impact of significant portal hypertension on liver resection
outcomes (5). Twenty-nine cirrhotic Child-Turcotte-Pugh
(CPT) class A patients who underwent LR were evaluated to
determine the role of increased portal pressure in developing
postoperative hepatic decompensation. Eleven of the 29 patients
developed persistent liver decompensationwithin the first three
months after surgery, and HVPG was the only independent
factor that predicted hepatic decompensation in a multivariate
analysis (p,0.001). Subsequently, the same researchers updated
their results, suggesting that either HVPG or clinical signs of
portal hypertension could be used to select HCC patients for
resection or liver transplantation (6). Note that patients with a
single tumor .5 cm do not fulfill the Milan criteria, and liver
transplantation is not usually considered a treatment alternative
(2,3,7). Therefore, the presence of portal hypertension as an
absolute criterion for selecting patients for liver transplantation,
rather than resection, is of most relevance to the subgroup of
patients who could undergo either resection or transplantation.
Given the limited efficacy of other treatment options for this
patient subset, such as transarterial chemoembolization,
patients with a single tumor .5 cm may still be best served
by liver resection, even in the presence of portal hypertension.
The study by Boleslawski et al. did not mention tumor number
or size in the 40 enrolled patients, and this information may aid
in interpreting their data and conclusions. Note that in their
series, not all of the patients performed poorly (despite liver
resection in the presence of a HVPG .10 mmHg), and portal
hypertension clinically-based (PH-CB) was not predictive of
patient outcomes.
In light of the uncertainties surrounding the role of portal
hypertension in selecting HCC patients for liver resection, we
recently undertook a multicenter (in Australia, Spain, and
Brazil), exploratory analysis of 105 CPT AHCC patients (with a
single nodule #5 cm on imaging) who were treated with
primary liver resection (unpublished data). After a median
follow up of 51 months (range, 1–159 months), the 1-, 3-, and 5-
year survival rates were 97%, 83%, and 66%, respectively. As in
other studies, significant portal hypertension was defined as
having an HVPG $10 mmHg or the presence of gastro-
esophageal varices, splenomegaly (spleen length$12 cm) with
a platelet count ,100,000/mm3, or the need for diuretics to
control ascites. PH-CB was defined with the same criteria but
without the HVPG variable. No pre-operative characteristic
predicted the likelihood of survival after assessing all of the
variables recommended by the Panel of Experts in HCC-Design
Clinical Trials (7). In other words, our results suggest that liver
resection for CPT A HCC patients with a single tumor #5 cm
offers survival rates similar to liver transplantation, indepen-
dent of any pre-operative characteristics (8).
We have summarized the published studies evaluating liver
resection for patients with cirrhosis and HCC (Table 1). It is
clear that the data regarding the prognostic factors for HCC
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patients undergoing liver resection are scarce. Current
recommendations for patient selection for liver resection versus
liver transplantation for tumors #5 cm are still based on the
original Barcelona group publication, which was based on a
retrospective analysis of a case series from the 1990s (5). Note
that given the limitations of retrospective studies, the robustness
of evidence supporting this findingmust be validated following
evidenced-based ranking systems (9). Basing recommendations
on the results of liver resection performed in the 1990s ignores
recent improvements in the perioperative care of cirrhotic
patients (10). These recommendations may also limit access to
liver resection for patientswho have no or limited access to liver
transplantation.
In conclusion, further well-designed trials are warranted
to evaluate the role of significant portal hypertension in
predicting liver resection outcomes for HCC patients.
Nevertheless, until further well-designed prospective stu-
dies are undertaken, the recommendations of the EASL–
HCC Clinical Practice Guidelines should remain in place.
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